Literature DB >> 14962433

Oculogyric crisis in patients taking cetirizine.

Frederick W Fraunfelder1, Frederick T Fraunfelder.   

Abstract

PURPOSE: To report oculogyric crisis in patients receiving cetirizine and inform clinicians on the characteristics of this drug-induced ocular side effect.
METHODS: For this retrospective, observational case series, case reports were collected from the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute, Portland, Oregon). The World Health Organization Causality Assessment Guide of Suspected Adverse Reactions was used to categorize the cases.
RESULTS: Nine cases were reported, with eight occurring in the pediatric age group. Dosage ranged from 5 to 10 mg orally and onset of symptoms ranged from 3 to 184 days. Six cases of oculogyric crisis had positive rechallenge data. Eight cases had complete neurologic consultation including radiographic studies.
CONCLUSIONS: Cetirizine can cause oculogyric crisis, especially in the pediatric age group. Extensive neurologic workups may be avoided if clinicians recognize this drug-induced ocular side effect.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14962433     DOI: 10.1016/S0002-9394(03)00869-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

Review 1.  Ocular toxicity from systemically administered xenobiotics.

Authors:  Mitan R Gokulgandhi; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-07-18       Impact factor: 4.481

Review 2.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects.

Authors:  Ranjan P Malhotra; Edward Meier; Gail Torkildsen; Paul J Gomes; Mark C Jasek
Journal:  Clin Ophthalmol       Date:  2019-02-19

Review 4.  Are we pharmacovigilant enough in ophthalmic practice?

Authors:  Ashok Dubey; Shailendra S Handu
Journal:  Indian J Ophthalmol       Date:  2013-05       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.